Drugs / PGI2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00291395 | Sep 2005 → ? | migraine disorder | Danish Headache Center | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04594629 Comparator | Nov 2020 → May 2021 | pulmonary hypertension | Ain Shams University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-04-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Generic Flolan® For Injection tevapharm.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGI2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04594629 ↗ |
| Known as | epoprostenol | “Patients of PGI2 group received nebulized PGI2 (epoprostenol), 20000 ng/ml” NCT04594629 ↗ |
| Known as | Flolan | “20000 ng/ml (Flolan; Glaxo Wellcome Inc, Research Triangle Park, NC)” NCT04594629 ↗ |
| Route | Intravenous | “intravenous administration of PGI2” NCT00291395 ↗ |